Vaccine safety: what systems are required to ensure public confidence in vaccines?

Allen C Cheng and Jim P Buttery
Med J Aust 2022; 217 (4): . || doi: 10.5694/mja2.51662
Published online: 15 August 2022

No single surveillance system is perfect, but integrating data from multiple sources can provide comprehensive and reliable signal detection

Although phase 3 pre‐licensing vaccine studies typically include tens of thousands of participants, they generally cannot detect rare adverse events following immunisation (AEFI). Further, participants in clinical trials are generally highly selected, and safety profiles may be different when programs are applied to broader populations. Robust systems for detecting AEFI (post‐marketing surveillance) are therefore essential when large scale vaccination programs are implemented.

  • 1 Monash University, Melbourne, VIC
  • 2 Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), Murdoch Children’s Research Institute, Melbourne, VIC


Competing interests:

No relevant disclosures.

  • 1. Gold MS, Effler P, Kelly H, et al. Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia. Med J Aust 2010; 193: 492‐493.‐convulsions‐after‐2010‐seasonal‐trivalent‐influenza‐vaccine‐implications
  • 2. Martin JH, Lucas C. Reporting adverse drug events to the Therapeutic Goods Administration. Aust Prescr 2021; 44: 2‐3.
  • 3. Clothier HJ, Lawrie J, Russell MA, et al. Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia. PLoS One 2019; 14: e0224702.
  • 4. Clothier HJ, Crawford NW, Russell M, et al. Evaluation of “SAEFVIC”, a pharmacovigilance surveillance scheme for the spontaneous reporting of adverse events following immunisation in Victoria, Australia. Drug Saf 2017; 40: 483‐495.
  • 5. World Health Organization. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. 2nd edition, 2019 update. (viewed June 2022).
  • 6. Hocking J, Chunilal SD, Chen VM, et al. The first known case of vaccine‐induced thrombotic thrombocytopenia in Australia. Med J Aust 2021; 215: 19‐20.e1.‐known‐case‐vaccine‐induced‐thrombotic‐thrombocytopenia‐australia
  • 7. Osowicki J, Morgan H, Harris A, et al. Guillain–Barre syndrome in an Australian state using both mRNA and adenovirus‐vector SARS‐CoV‐2 vaccines. Ann Neurol 2021; 90: 856‐858.
  • 8. Wong J, Sharma S, Yao JV, et al. COVID‐19 mRNA vaccine (Comirnaty)‐induced myocarditis. Med J Aust 2022; 216: 122‐123.‐19‐mrna‐vaccine‐comirnaty‐induced‐myocarditis
  • 9. Cashman P, Macartney K, Khandaker G, et al. Participant‐centred active surveillance of adverse events following immunisation: a narrative review. Int Health 2017; 9: 164‐176.
  • 10. Deng L, Glover C, Dymock M, et al. The short term safety of COVID‐19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. Med J Aust 2022; 217: 195‐202.
  • 11. Pillsbury AJ, Glover C, Jacoby P, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open 2018; 8: e023263.
  • 12. Phillips A, Carlson S, Danchin M, et al. From program suspension to the pandemic: a qualitative examination of Australia’s vaccine pharmacovigilance system over 10 years. Vaccine 2021; 39: 5968‐5981.
  • 13. King C, Leask J. The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia. BMC Public Health 2017; 17: 106.
  • 14. Mesfin YM, Cheng AC, Enticott J, et al. Post‐vaccination healthcare attendance rate as a proxy measure for syndromic surveillance of adverse events following immunisation. Aust N Z J Public Health 2021; 45: 101‐107.
  • 15. Mesfin YM, Cheng A, Lawrie J, Buttery J. Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review. BMJ Glob Health 2019; 4: e001065.
  • 16. Lai LY, Arshad F, Areia C, et al. Current approaches to vaccine safety using observational data: a rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance‐for Vaccines) study design. Front Pharmacol 2022; 13: 837632.
  • 17. Crawford NW, Hodgson K, Gold M, et al; AEFI‐CAN network. Adverse events following HPV immunization in Australia: establishment of a clinical network. Hum Vaccin Immunother 2016; 12: 2662‐2665.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.